Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia

Pushpam, Deepam; Rajput, Nishi; Chopra, Anita; Vishnubhatla, Sreenivas; Kumari, Mamta; Kumar, Rajive; Bakhshi, Sameer

doi:10.1080/08880018.2019.1594469

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, antitumor immune status has been recognized as affecting patients’ prognosis in many malignant diseases including hematological malignancy. During the same time period, it was found that absolute lymphocyte count (ALC) of peripheral blood could reflect host immune function and predict patients’ prognosis in several diseases [ 8 – 11 ]. A reduced lymphocyte count is considered a poor prognostic factor in malignancy, suggesting an important role for immunosurveillance and clearance of lymphocytes [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma

Liu

Wang

2020

Med Sci Monit

View full text Add to dashboard Cite

Background To find economical and clinically available immune-related prognostic markers that could predict the overall survival (OS) of newly diagnosed multiple myeloma (NDMM) in the new drug era. Material/Methods Absolute lymphocyte count (ALC) and absolute monocyte count (AMC) were measured in routine blood samples from 102 patients with NDMM, and the lymphocyte-monocyte ratio (LMR) was derived. All the patients were receiving bortezomib-based chemotherapy as induction treatment. Log-rank testing was used for comparing the differences between groups. Univariate and multivariate tests were used to identify prognostic markers. Results The median ALC and LMR values at diagnosis were 1.43×10 9 /L and 3.7, respectively, and served as the cutoff point. As prognostic factors, ALC, LMR, and a new staging system combining ALC and the ISS staging system (L-ISS) were expected to have a significant impact on predicting OS. Furthermore, multivariate analysis showed that ALC ≥1.43×10 9 /L (hazard ratio [HR]: 0.223; 95% confidence interval [CI]: 0.071–0.705; P =0.011), LMR ≥3.7 (HR: 0.363; 95% CI: 0.139–0.947; P =0.038), and L-ISS late stage (HR: 1.619; 95% CI: 1.065–2.743; P =0.027) were independent predictors for OS. Conclusions ALC and LMR can serve as surrogate markers for patients’ antitumor immunity at the initial diagnosis of multiple myeloma. A new immune-related staging system, L-ISS, which combines ALC and the ISS staging system, can predict clinical outcomes in patients who are receiving bortezomib-based chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma

Liu

Wang

2020

Med Sci Monit

View full text Add to dashboard Cite

show abstract

Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia

et al. 2021

View full text Add to dashboard Cite

Several studies have reported an association between the rapidity of reduction in peripheral blood blast count or recovery of normal hematopoiesis and treatment outcome during therapy in children with acute lymphoblastic leukemia (ALL). However, little is known about the impact of both of these aspects on prognosis in pediatric ALL. Accordingly, the purpose of this study was to evaluate whether the combined use of blood blast count and platelet count could predict event-free survival (EFS) and overall survival (OS) when minimal residual disease (MRD) detection was not available. A total of 419 patients aged 0 to 14 years diagnosed and treated for ALL between 2011 and 2015 were enrolled. Patients with a blast count ≥0.1 × 10 9 /L on day 8 exhibited significantly lower survival rates than that in those with blast counts <0.1 × 10 9 /L. The EFS and OS in patients with platelet count ≥100 × 10 9 /L on day 33 were significantly higher than those with platelet counts <100 × 10 9 /L. In univariate and multivariate analyses, patients with low blast count on day 8 and high platelet count on day 33 were significantly associated with better EFS and OS. The combination of blast cell count on day 8 and platelet count on day 33 demonstrated a strong association with MRD-based risk stratification. Complete blood count is an inexpensive, easy to perform, and reliable measurement in children with ALL. The combination of blast count and platelet count during and after induction chemotherapy was a significant and independent prognostic factor for treatment outcome in pediatric ALL.

show abstract

Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia

Cited by 2 publications

References 23 publications

Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma

Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma

Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia

Contact Info

Product

Resources

About